INmune Bio Inc (INMB) can make a big difference with a little luck

With 0.17 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.25 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.12 whereas the lowest price it dropped to was $4.88. The 52-week range on INMB shows that it touched its highest point at $14.74 and its lowest point at $4.45 during that stretch. It currently has a 1-year price target of $19.83. Beta for the stock currently stands at 1.79.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INMB was up-trending over the past week, with a rise of 7.24%, but this was down by -22.38% over a month. Three-month performance dropped to -28.72% while six-month performance fell -48.72%. The stock lost -47.81% in the past year, while it has lost -56.57% so far this year. A look at the trailing 12-month EPS for INMB yields -2.18 with Next year EPS estimates of -2.04. For the next quarter, that number is -0.56. This implies an EPS growth rate of -37.43% for this year and 10.94% for next year.

Float and Shares Shorts:

At present, 17.95 million INMB shares are outstanding with a float of 15.76 million shares on hand for trading. On 2024-11-15, short shares totaled 3.57 million, which was 1609.0 higher than short shares on 1728950400. In addition to Dr. Raymond Joseph Tesi M.D. as the firm’s Co-Founder, President, CEO, Chief Medical Officer & Chairman, Mr. David J. Moss M.B.A. serves as its CFO, Treasurer & Secretary.

Institutional Ownership:

Through their ownership of 0.24344 of INMB’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, INMB reported revenue of $0.0 and operating income of -$12286000.0. The EBITDA in the recently reported quarter was -$12286000.0 and diluted EPS was $nan.

Analysts Ratings:

In the same way, a target price assigned to a stock can also reveal much about its potential. With INMB analysts setting a high price target of 22.0 and a low target of 16.0, the average target price over the next 12 months is 19.83333. Based on these targets, INMB could surge 349.9% to reach the target high and rise by 227.2% to reach the target low. Reaching the average price target will result in a growth of 305.59% from current levels.

Analysts have provided yearly estimates in a range of -$2.295 being high and -$2.295 being low. For INMB, this leads to a yearly average estimate of -$2.295.